Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniel Wetterskog
Observed names:
D Wetterskog,
D. Wetterskog,
Wetterskog, Daniel
Institution:
University College London
Observed institutions:
Institute of Cancer Research,
University of Occupational and Environmental Health Japan,
London Cancer,
Institute of Cancer Research,
Chiba Cancer Center Research Institute,
University College London,
Chalmers University of Technology,
University of Gothenburg
show all 8
ORCID:
0000-0003-4163-6438
Observed ORCID:
0000-0003-4163-6438
OpenAlex ID:
A5087812629
Plasma AR and abiraterone-resistant prostate cancer
2015
·
Alessandro Romanel
, Delila Gasi Tandefelt
, et al.
·
Science Translational Medicine
·
444
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis
2007
·
Lars Johan Nissen
, Renhai Cao
, et al.
·
Journal of Clinical Investigation
·
296
PDF
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
2017
·
V. Conteduca
, D. Wetterskog
, et al.
·
Annals of Oncology
·
275
Emerging therapeutic targets in endometrial cancer
2011
·
Konstantin J. Dedes
, Daniel Wetterskog
, et al.
·
Nature Reviews Clinical Oncology
·
272
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
2010
·
Konstantin J. Dedes
, Daniel Wetterskog
, et al.
·
Science Translational Medicine
·
256
Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations
2011
·
Konstantin J. Dedes
, Paul M. Wilkerson
, et al.
·
Cell Cycle
·
199
PDF
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers
2011
·
Daniel Wetterskog
, Maria Angeles Lopez‐Garcia
, et al.
·
The Journal of Pathology
·
180
Functional Viability Profiles of Breast Cancer
2011
·
Rachel Brough
, Jessica R. Frankum
, et al.
·
Cancer Discovery
·
140
PDF
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
2021
·
S. Taavitsainen
, N. Engedal
, et al.
·
Nature Communications
·
129
PDF
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges
2022
·
Blanca Trujillo
, Anjui Wu
, et al.
·
British Journal of Cancer
·
111
PDF
Genome-wide plasma DNA methylation features of metastatic prostate cancer
2020
·
Anjui Wu
, Paolo Cremaschi
, et al.
·
Journal of Clinical Investigation
·
103
Functional characterization of the 19q12 amplicon in grade III breast cancers
2012
·
Rachael Natrajan
, Alan Mackay
, et al.
·
Breast Cancer Research
·
89
PDF
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
2018
·
Vincenza Conteduca
, Anuradha Jayaram
, et al.
·
European Urology
·
85
PDF
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
2021
·
A. Jayaram
, A. Wingate
, et al.
·
Annals of Oncology
·
64
PDF
Loss of Redness (a*) as a Tool To Follow Hemoglobin-Mediated Lipid Oxidation in Washed Cod Mince
2004
·
Daniel Wetterskog
, Ingrid Undeland
·
Journal of Agricultural and Food Chemistry
·
64
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
2018
·
Enrique González-Billalabeitia
, Vincenza Conteduca
, et al.
·
Prostate Cancer and Prostatic Diseases
·
49
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
2013
·
D Wetterskog
, K-K Shiu
, et al.
·
Oncogene
·
49
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
2025
·
Emily Grist
, Peter Dutey-Magni
, et al.
·
Cell
·
46
PDF
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations
2012
·
Daniel Wetterskog
, Paul M Wilkerson
, et al.
·
Histopathology
·
44
PDF
Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study
2010
·
Konstantin J. Dedes
, Maria-Angeles Lopez-Garcia
, et al.
·
Breast Cancer Research and Treatment
·
44
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling
2013
·
Joan Chang
, Monica M Nicolau
, et al.
·
Breast Cancer Research
·
40
PDF
Functional characterization of EMSY gene amplification in human cancers
2011
·
Paul M Wilkerson
, Konstantin J Dedes
, et al.
·
The Journal of Pathology
·
38
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
2020
·
Vincenza Conteduca
, Daniel Wetterskog
, et al.
·
British Journal of Cancer
·
36
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
2025
·
Silke Gillessen
, Laura Murphy
, et al.
·
The Lancet Oncology
·
35
PDF
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis
2019
·
Anuradha Jayaram
, Anna Wingate
, et al.
·
JCO Precision Oncology
·
35
Show more works
View as search
Works count:
124
Citation count:
3,632
H-index:
29
I10-index:
45
Year
Topic
Type
